Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colposeptine in Bacterial Vaginosis
NCT01153958Phase 4Terminated
- Sponsor
- Merck KGaA
- Start
- Jul 2010
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of chlorquinaldol + promestriene in bacterial vaginosis (BV) (2 arms), sponsored by Merck KGaA. Primary endpoint: Percentage of Participants With Relapse. Started Jul 2010; status: terminated.
02
Drugs
chlorquinaldol + promestriene
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on NCT01153958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01153958.